Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis
about
Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypesMicrobiology of airway disease in a cohort of patients with cystic fibrosis.Sphingobacterium respiratory tract infection in patients with cystic fibrosis.Development and validation of a prognostic model for predicting 30-day mortality risk in medical patients in emergency department (ED).Intracardiac abscess with cutaneous fistula secondary to ventricular septal defect repair simulating sternal wound infection.The changing microbial epidemiology in cystic fibrosis.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Aerobic degradation of mercaptosuccinate by the gram-negative bacterium Variovorax paradoxus strain B4.Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosisLow rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient, France.Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.Fourier transform infrared spectroscopy for rapid identification of nonfermenting gram-negative bacteria isolated from sputum samples from cystic fibrosis patientsIntensive care management of the patient with cystic fibrosis.Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease.Update on antibiotics for infection control in cystic fibrosis.Current dilemmas in antimicrobial therapy in cystic fibrosis.Fluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients.First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.Use of 16S rRNA gene sequencing for identification of nonfermenting gram-negative bacilli recovered from patients attending a single cystic fibrosis center.Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.A pan-genomic approach to understand the basis of host adaptation in Achromobacter.Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia.Distribution of innate efflux-mediated aminoglycoside resistance among different Achromobacter species.Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.Complete Genome Sequence of Achromobacter xylosoxidans MN001, a Cystic Fibrosis Airway Isolate.Pulmonary Infection Caused by Achromobacter xylosoxidans in a Patient with Carcinoma of Epiglottis: A Rare Case.Efficacy of aerosolized peroxyacetic acid as a sanitizer of lettuce leaves.Achromobacter xylosoxidans infection presenting as a pulmonary nodule mimicking cancer.Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.Discriminating typical and atypical cystic fibrosis-related bacteria by multiplex PNA-FISH.Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002).
P2860
Q21132701-4B695FFB-536E-4A52-B04C-6A831DEEC57DQ25256069-F925A383-284B-49F5-807D-538AC140364DQ33520547-3840987F-D70C-421D-B4E6-52D8CAD4197EQ33555539-F22EE304-4B0D-49A6-8BB8-3465487376B8Q33766221-19A77A23-0911-4371-865D-BEC289A478E6Q33825634-80D43600-45D3-46CF-8443-F9B6742FB64DQ34297656-49F4383D-C51E-4EDE-9724-43A86E4D7B15Q34484230-1505A44C-CDC3-4CFE-8D6A-E79511A2EF1AQ34568983-5FC3FBDD-FCA8-4E21-B534-6B24393F8595Q34956792-675E7532-DCB5-44EB-9652-8CAE58FD9887Q35005445-AD1AA4F4-2C8D-4BE1-B74A-182AA8A5E799Q35094033-710014A2-B845-484E-B5EF-F013647E4712Q35213050-C082D599-ADE3-4ED3-820C-403B190F2DFDQ36023539-D69A7924-FB34-4920-829D-33C921DA84E6Q36670892-677B4288-1486-4E5C-BF75-0EC982C993C5Q36688818-B4AB0FC5-8501-44DD-BB2C-25F1E1117A75Q36771148-ED3FEE81-2CF0-4CDF-B604-D93FB9C9BAA2Q36845344-7AE16195-D117-4932-B050-541BBA74FF2DQ37149666-841216AB-C37D-4FBA-9418-29D77721EEFEQ37161460-3703539B-BDFA-47DA-A9A6-0DA8A36DC476Q37608274-EB1D7EE2-BF22-401C-8D8E-935332117329Q38042719-65B84CA8-2E68-4E81-9B21-961269C07637Q38476154-EF5A76B9-F782-4B49-99C1-FE84446A0039Q38627088-85CA5838-015F-4EC4-B719-70B731157B95Q39651481-91E35BE6-878A-47EA-B344-D1E4C8906D4EQ39665032-8DAE746E-C1C7-4129-99BB-E385C435F621Q39732748-EC2DDB9F-3CBA-4989-ADD0-9AAF3C3C0959Q40262334-D7F4A2B1-E5B4-43A4-84CC-FC3C2216BFC2Q40468493-B83F4B50-0D0D-4838-95DD-18A67FC69040Q41018046-972E4670-71E1-48DE-860C-D0637CF2378BQ41836400-D9C612D5-63D7-47BC-9B9C-7B6A25CB3ACAQ42130118-C106D025-CB9C-4BF8-8169-A282E78EC24CQ42529898-E6E6149C-377C-4E91-8E95-8EFBCAAE04CBQ42709543-BB7CF1B5-01D1-466A-88A2-F2811D618FC2Q42718721-2AC907D5-F623-4C85-9868-7E3F11CF7F11Q42785781-1F634A75-8C25-4B2B-A698-4FBFBC5B013EQ42850284-BE4E99A7-90AE-41E8-9FF5-3B9ED07CA45AQ42948700-E2AE4305-F7D7-406D-BE7C-83732B552E67Q46495945-FCAF980C-63DB-4F56-9F3A-E75238E1C713Q46815367-2FA4A6DF-5383-4099-A6B2-4C8B92F04901
P2860
Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Identification and antimicrobi ...... patients with cystic fibrosis
@ast
Identification and antimicrobi ...... patients with cystic fibrosis
@en
Identification and antimicrobi ...... patients with cystic fibrosis
@nl
type
label
Identification and antimicrobi ...... patients with cystic fibrosis
@ast
Identification and antimicrobi ...... patients with cystic fibrosis
@en
Identification and antimicrobi ...... patients with cystic fibrosis
@nl
prefLabel
Identification and antimicrobi ...... patients with cystic fibrosis
@ast
Identification and antimicrobi ...... patients with cystic fibrosis
@en
Identification and antimicrobi ...... patients with cystic fibrosis
@nl
P2093
P2860
P3181
P1476
Identification and antimicrobi ...... patients with cystic fibrosis
@en
P2093
P San Gabriel
S Whittier
P2860
P304
P3181
P356
10.1128/JCM.39.11.3942-3945.2001
P407
P577
2001-11-01T00:00:00Z